TrialArthritis research & therapy2021

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

Jonathan Kay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.